Zynerba Pharmaceuticals, Inc.
TREATMENT OF AUTISM WITH CANNABIDIOL
Last updated:
Abstract:
The present technology relates to a method of treating one or more behavioral symptoms of Fragile X Syndrome Autism Spectrum Disorder (ASD) in a subject by transdermally administering an effective amount of cannabidiol (CBD) to the subject wherein one or more behavioral symptoms of Fragile X Syndrome ASD are treated in the subject.
Status:
Application
Type:
Utility
Filling date:
14 May 2019
Issue date:
29 Aug 2019